Effects of the Addition of Bevacizumab or Iniparib to Standard Chemotherapy for Breast Cancer, Including Triple-Negative Disease, in the Neoadjuvant and Metastatic Settings


Effects of the Addition of Bevacizumab or Iniparib to Standard Chemotherapy for Breast Cancer, Including Triple-Negative Disease, in the Neoadjuvant and Metastatic Settings
Slides from ASCO 2011 presentations and comments from Drs Geyer, Burstein and Gralow

Bear HD et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. Proc ASCO 2011;Abstract LBA1005.

Gerber B et al. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 686 triple-negative primary breast cancers: Secondary endpoint analysis of the GeparQuinto study (GBG 44). Proc ASCO 2011;Abstract 1006.

Dr Geyer is Chief Medical Officer of the Statewide Clinical Trials Network of Texas (CTNeT) in Houston, Texas.

Dr Burstein is Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.